Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Shahsavand Ananloo, Esmaeil ^a   Ghaeli, Padideh ^a   Kamkar, Mohammad Zaman ^b   Sadeghi, Majid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Body weight; Cholesterol; Serotonin reuptake inhibitors; Tricyclic antidepressants; Triglyceride

Indexed keywords

CHOLESTEROL; FLUOXETINE; IMIPRAMINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84872765214     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-4     Document Type: Article

References (24)

1. Comorbidity of DSM-III-R major depressive disorder in the general population. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG, Br J Psychiatry 1996 168 Suppl 30 17 30
2. The National Comorbidity Survey: Psychiatric Epidemiology. Kessler RC, Walters EE, New York, NY: John Wiley & Sons, Tsaung MT, Tohen M, 2 2002 343 362
3. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. JAMA 2003 289 3095 3105 10.1001/jama.289.23. 3095 12813115 (Pubitemid 37432885)
4. Clinical pharmacokinetics of fluoxetine. Altamura AC, Moro AR, Percudani M, Clin Pharmacokinet 1994 26 201 214 10.2165/00003088-199426030-00004 8194283 (Pubitemid 24081625)
5. Cyclic antidepressants: Clinical Pharmacokinetics Pocket Handbook. Devane LC, Bethesda, MD:American Society of Health-System Pharmacy (ASHP), Murphy EJ, 1993
6. Fluoxetine versus other types of pharmacotherapy for depression. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Cochrane Database Syst Rev 2005 4 D004185 16235353
7. Changes in weight during a 1 year trial of fluoxetine. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley CM, Am J Psychiatry 1999 156 8 1170 1176 10450256 (Pubitemid 29374875)
8. Effect of prolonged trifluoperazine, imipramine and haloperidol administration on serum cholesterol. An experimental study in rabbits. Bala S, Garg KN, Pharmacology 1976 14 385 389 10.1159/000136619 1031212
9. Amitriptyline, weight gain and carbohydrate craving: a side effect. Paykel ES, Mueller PS, De la Vergne PM, Br J Psychiatry 1973 123 501 507 10.1192/bjp.123.5.501 4588039
10. Weight gain: a side-effect of tricyclic antidepressants. Berken GH, Weinstein DO, Stern WC, J Affect Disord 1984 7 133 138 10.1016/0165-0327(84) 90031-4 6238068 (Pubitemid 14028739)
11. Weight gain with antidepressants and Raeder lithium. Garland EJ, Remick RA, Zis AP, J Clin Psychopharmacol 1988 8 323 330 3053797
12. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland health Study. Raeder MB, Bjelland I, Emil Vollset S, Steen VM, J Clin Psychiatry 2006 67 1974 1982 10.4088/JCP.v67n1219 17194277 (Pubitemid 46048196)
13. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM, Neurosci Lett 2006 395 185 190 10.1016/j.neulet.2005.10. 096 16324787 (Pubitemid 43213141)
14. Doxepin increases serum cholesterol levels. Roessner V, Demling J, Bleich S, Can J Psychiatry 2004 49 1 74 75 14763684 (Pubitemid 38182029)
15. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Pollock BG, Perel JM, Paradis CF, Fasiczka AL, Reynolds CF 3rd, Psychopharmacol Bull 1994 30 145 150 7831447 (Pubitemid 24331378)
16. Fluoxetine decreased serum total cholesterol and triglyceride levels in a hypercholesterolemic patient with postpartum depression. Ghaeli P, Shahsavand E, Sadeghi M, Khalili H, Iranian Journal of Psychiatry 2006 1 84 85
17. Chronic imipramine treatment and weight gain. Fernstrom MH, Krowinski RL, Kupfer DJ, Psychiatry Res 1986 17 269 273 10.1016/0165-1781(86)90074-0 3714910 (Pubitemid 16109697)
18. Imipramine and weight gain during the treatment of recurrent depression. Frank E, Kupfer DJ, Bulik CM, Levenson JA, J Affect Disord 1990 20 165 172 10.1016/0165-0327(90)90140-4 2148336 (Pubitemid 20350928)
19. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. McGuirk J, Silverstone T, Int J Obesity Relat Metab Disord 1990 14 4 361 372 (Pubitemid 20212177)
20. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Harto NE, Spera KF, Branconnier RJ, Psychopharmacol Bull 1988 24 220 223 3264922
21. Weight gain and antidepressants. Fava M, J Clin Psychiatry 2000 61 Suppl 11 37 41 10926053 (Pubitemid 30616693)
22. Weight gain during antidepressant therapy. Sep-Kowalikowa B, Prokopowicz A, Pankiewicz P, Psychiatr Pol 1992 26 1-2 37 43 1298003
23. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC, J Clin Psychiatry 2000 61 863 867 10.4088/JCP.v61n1109 11105740
24. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH, Expert Opin Drug Saf 2006 5 523 537 10.1517/14740338.5.4.523 16774491 (Pubitemid 44468450)